Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece.
Gourzoulidis GeorgeCharalampos TzanetakosIoannis IoannidisVasilis TsimihodimosViana DiogoGeorge KarpouzosGiannis PapageorgiouGeorgia KourlabaPublished in: Clinical drug investigation (2021)
Empagliflozin was estimated to be a highly cost-effective treatment option compared to dapagliflozin for the treatment of T2DM patients with established CVD in Greece.